<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 13, Issue 3</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>July - September, 2021</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2022</Year>
<Month>06</Month>
<Day>7</Day>
</PubDate>
<ArticleType>Pharmaceutics</ArticleType>
<ArticleTitle>Simultaneous estimation of simvastatin and fenofibrate from their combined dosage form by ultraviolet–visible spectroscopy using simultaneous equation method</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>117</FirstPage>
<LastPage>121</LastPage>
<AuthorList>
<Author>
<FirstName>Geeta</FirstName>
<LastName>Rajput</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Saranjit</FirstName>
<LastName>Singh</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Balak Das</FirstName>
<LastName>Kurmi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Objective: This research paper describes a simple, precise, and accurate UV-Vis Spectrophotometric method was developed and validated for simultaneous estimation of simvastatin (SIM) and fenofibrate (FEN) from their combination dosage form.
Method: This method includes forming and solving a simultaneous equation using 238 nm and 287 nm as two analytical wavelengths (__ampersandsignlambda;max of the drugs) of detection. Both the drugs followed Beer-Lambert’s law over the concentration range 0.60-3.60 __ampersandsignmu;g/mL for simvastatin and 4.35-26.10 __ampersandsignmu;g/mL for fenofibrate, respectively.
Results: Validation of the new developed method was done by linearity, precision, accuracy, limit of detection, limit of quantitation and robustness as per ICH guidelines and the results of the analysis were validated statistically.
Conclusion: The available information from the research will be very informative towards the multi-component analysis of these drugs and will open new paradigms in the upcoming research in the field of analysis.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Fenofibrate, simultaneous equation method, simvastatin, ultraviolet– visible spectroscopy</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13782&title=Simultaneous estimation of simvastatin and fenofibrate from their combined dosage form by ultraviolet–visible spectroscopy using simultaneous equation method</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1. Patel A, Macwana C, Parmar V, Patel S. Simultaneous determination of atorvastatin calcium, ezetimibe, and fenofibrate in a tablet formulation by HPLC. J AOAC Int 2012;95:419-23.
2. Patel B, Jadav A, Solanki H, Parmar S, Parmar V, Captain A, et al. Development and validation of derivative spectroscopic method for the simultaneous estimation of rosuvastatin calcium and fenofibrate in tablet. Int J Pharma Res Rev 2013;2:1-6.
3. Sharp M, Ormrod D, Jarvis B. . Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. Am J Cardiovasc Drugs 2002;2:125-32.
4. Packard CJ. Overview of fenofibrate. Eur Heart J 1998;19:A62-5.
5. Jain N, Jain R, Swami H, Jain DK. RP-HPLC method for simultaneous estimation of simvastatin and ezetimibe in bulk drug and its combined dosage form. Int J Pharm Pharm Sci 2008;1:29-31.
6. Todd PA, Goa KL. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990;40:583-607.
7. Pedersen TR, Tobert JA. Simvastatin: A review. Expert Opin Pharmacother 2004;5:2583-96.
8. Behera S, Ghanty S, Ahmad F, Santra S, Banerjee SJ. UV-visible spectrophotometric method development and validation of assay of paracetamol tablet formulation. Int J Pharm Sci Res 2012;3:151-7.
9. Gaikwad PV, Sawant SD, Ghante MR, Munot NM. Three simple spectrometric methods for fenofibrate in tablet form. J Pharm Res 2011;4:1741-2.
10. Giriraj P, Sivakkumar TJ. New simple spectrophotometric method for the simultaneous estimation of paracetamol and flupirtine maleate in pure and pharmaceutical dosage form. Int J Spectrosc 2014;2014:968420.
11. Gupta KR, Askarkar SS, Rathod PR, Wadodkar SG. Validated spectrophotometric determination of fenofibrate in formulation. Pelagia Res Lib 2010;1:173-8.
12. Lotfy HM. Determination of simvastatin and ezatimibe in combined tablet dosage forms by constant center spectrophotometric method. Int J Pharm Pharm Sci 2012;4:673-9.
13. Porfire A, Muntean D, Achim M, Vlase L, Tomuta IJ. Simultaneous quantification of simvastatin and excipients in liposomes using near infrared spectroscopy and chemometry. J Pharm Biomed Anal 2015;107:40-9.
14. Rajput S, Raj HJ. Simultaneous spectroscopic estimation of ezetimibe and simvastatin in tablet dosage forms. Indian J Pharm Sci 2007;69:759.
15. Partani P, Verma SM, Monif TJ. Development and validation of an LC-MS-MS method for determination of simvastatin and simvastatin acid in human plasma: Application to a pharmacokinetic study. J Chromatogr Sci 2016;54:1385-96.
16. Bhinge S, Malipatil S, Jondhale A, Hirave R, Savali AJ. A new approach to the RP-HPLC method for simultaneous estimation of atorvastatin calcium and fenofibrate in pharmaceutical dosage forms. J Chem 2012;9:1223-9.
17. Jain N, Raghuwanshi R, Jain DJ. Development and validation of RP-HPLC method for simultaneous estimation of atorvastatin calcium and fenofibrate in tablet dosage forms. Indian J Pharm Sci 2008;70:263.
18. Ladke A, Ingle A, Ranaware P, Damle MJ. Development and validation of stability indicating HPLC method for rosuvastatin calcium and fenofibrate in combination. Asian J Res Chem 2012;5:606-10.
19. Novand;aacute;kovand;aacute; L, and;Scaron;atand;iacute;nskand;yacute; D, Solich PJ. HPLC methods for the determination of simvastatin and atorvastatin. TrAC Trends Anal Chem 2008;27:352-67.
20. Kumar TP, Padmakar SJ. Development and validation of HPTLC method for niacin and simvastatin in binary combination. Adv Biosci Biotechnol 2010;1:12018.
21. Dixit RP, Barhate CR, Nagarsenker MS. Stability-indicating HPTLC method for simultaneous determination of ezetimibe and simvastatin. Chromatographia 2008;67:101-7.
22. Alamri RG, Mohsin K, Ahmad A, Raish M, Alanazi FK. Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics. Saudi Pharm J 2017;25:128-35.
23. Kadav A, Vora DJ. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets. J Pharm Biomed Anal 2008;48:120-6.
24. Breaux J, Jones K, Boulas PJ. Analytical methods development and validation. J Anal Bioanal Tech 2003;1:6-13.
25. Badyal P, Sharma C, Kaur N, Shankar R, Pandey A, Rawal RJ. Analytical techniques in simultaneous estimation: An Overview. Aust J Anal Pharm Chem 2015;2:1037.
26. Borman P, Elder DJ. Q2 (R1) Validation of Analytical Procedures. Netherlands: European Medicines Agency; 2017. p. 127-66.</References>
</References>
</Journal>
</Article>
</ArticleSet>